The major conclusion of our study is that MCL1-M can identify a subpopulation of myeloma patients sensitive to anthracyclines, and in vitro results demonstrate that anthracycline-sensitive myeloma cells can be treated together with IFN-α therapy to further promote tumor cell apoptosis. This evidence concerns the gene MCL1 and plasma cell myeloma.